Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders

  • Authors: Lashgari N.1, Momeni Roudsari N.1, Momtaz S.2, Niazi Shahraki F.1, Zandi N.3, Pazoki B.4, Farzaei M.5, Ghasemi M.6, Abdollahi M.7, Abdolghaffari A.H.8
  • Affiliations:
    1. Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University Pharmaceutical Sciences Branch
    2. Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR
    3. Department of Pharmacology,, Tehran University of Medical Sciences
    4. Department of Pharmacology, Tehran University of Medical Sciences
    5. Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences
    6. Department of Neurology, University of Massachusetts School of Medicine
    7. Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, Tehran University of Medical Sciences
    8. Department of Toxicology & Pharmacology, Faculty of Pharmacy,, Islamic Azad University Pharmaceutical Sciences Branch
  • Issue: Vol 25, No 13 (2024)
  • Pages: 1632-1650
  • Section: Biotechnology
  • URL: https://rjeid.com/1389-2010/article/view/644504
  • DOI: https://doi.org/10.2174/0113892010261502231102040149
  • ID: 644504

Cite item

Full Text

Abstract

Background:Visceral hypersensitivity (VH) is an overreaction of the gastrointestinal (GI) tract to various stimuli and is characterized by hyperalgesia and/or allodynia. VH contributes to the etiology of many GI dysfunctions, particularly irritable bowel syndrome (IBS). Although the exact mechanisms underlying VH are yet to be found, inflammation and oxidative stress, psychosocial factors, and sensorimotor alterations may play significant roles in it.

Objective:In this review, we provide an overview of VH and its pathophysiological function in GI disorders. Adverse effects of synthetic drugs may make herbal agents a good candidate for pain management. Therefore, in this review, we will discuss the efficacy of herbal agents in the management of VH with a focus on their anti-inflammatory and antioxidant potentials.

Methods:Data were extracted from clinical and animal studies published in English between 2004 and June, 2020, which were collected from PubMed, Google Scholar, Scopus, and Cochrane Library.

Results:Overall, Radix, Melissia, Glycyrrhizae, Mentha, and Liquorice were the most efficient herbals for VH management in IBS and dyspepsia, predominantly through modulation of the mRNA expression of transient receptor potential vanilloid type-1 (TRPV1) and suppression of 5- hydroxytryptamine 3 (5-HT3) or the serotonin receptors.

Conclusion:Considering the positive effects of herbal formulations in VH management, further research on novel herbal and/or herbal/chemical preparations is warranted.

About the authors

Naser-Aldin Lashgari

Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University Pharmaceutical Sciences Branch

Email: info@benthamscience.net

Nazanin Momeni Roudsari

Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University Pharmaceutical Sciences Branch

Email: info@benthamscience.net

Saeideh Momtaz

Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR

Email: info@benthamscience.net

Faezeh Niazi Shahraki

Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University Pharmaceutical Sciences Branch

Email: info@benthamscience.net

Nadia Zandi

Department of Pharmacology,, Tehran University of Medical Sciences

Email: info@benthamscience.net

Benyamin Pazoki

Department of Pharmacology, Tehran University of Medical Sciences

Email: info@benthamscience.net

Mohammad Farzaei

Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

Mehdi Ghasemi

Department of Neurology, University of Massachusetts School of Medicine

Email: info@benthamscience.net

Mohammad Abdollahi

Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, Tehran University of Medical Sciences

Email: info@benthamscience.net

Amir Hossein Abdolghaffari

Department of Toxicology & Pharmacology, Faculty of Pharmacy,, Islamic Azad University Pharmaceutical Sciences Branch

Author for correspondence.
Email: info@benthamscience.net

References

  1. Farzaei, M.H.; Bahramsoltani, R.; Abdollahi, M.; Rahimi, R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J. Neurogastroenterol. Motil., 2016, 22(4), 558-574. doi: 10.5056/jnm16001 PMID: 27431236
  2. Greenwood-van meerveld, Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. Neurogastroenterol. Motil., 2007, 19(s2)(Suppl. 2), 13-18. doi: 10.1111/j.1365-2982.2007.00964.x PMID: 17620083
  3. Yam, M.; Loh, Y.; Tan, C.; Khadijah Adam, S.; Abdul Manan, N.; Basir, R. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int. J. Mol. Sci., 2018, 19(8), 2164. doi: 10.3390/ijms19082164 PMID: 30042373
  4. Feng, B.; La, J.H.; Schwartz, E.S.; Gebhart, G.F. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 302(10), G1085-G1098. doi: 10.1152/ajpgi.00542.2011 PMID: 22403791
  5. Akhtar, M.S.; Aslam, M. Anthelmintic efficacies of total alkaloids and glycosides isolated from Punica granatum fruit-rind (anar); Pakistan J. Agricul. Sci, 1988.
  6. Liu, S.; Hagiwara, S.I.; Bhargava, A. Early‐life adversity, epigenetics, and visceral hypersensitivity. Neurogastroenterol. Motil., 2017, 29(9), e13170. doi: 10.1111/nmo.13170 PMID: 28782197
  7. Holzer, P.; Farzi, A.; Hassan, A.M.; Zenz, G.; Jačan, A.; Reichmann, F. Visceral inflammation and immune activation stress the brain. Front. Immunol., 2017, 8, 1613. doi: 10.3389/fimmu.2017.01613 PMID: 29213271
  8. Deiteren A.; de Wit, A.; van der Linden, L.; De Man, JG.; Pelckmans, P.A.; De Winter BY Irritable bowel syndrome and visceral hypersensitivity: risk factors and pathophysiological mechanisms. Acta Gastroenterol. Belg., 2016, 79(1), 29-38.
  9. Zhou, Q.; Verne, G.N. New insights into visceral hypersensitivity—clinical implications in IBS. Nat. Rev. Gastroenterol. Hepatol., 2011, 8(6), 349-355. doi: 10.1038/nrgastro.2011.83 PMID: 21643039
  10. Rexwinkel, R.; Zeevenhooven, J.; van Etten-Jamaludin, F.S.; Benninga, M.A.; Tabbers, M.M. Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain – not otherwise specified: a systematic review. Expert Opin. Drug Saf., 2019, 18(2), 111-125. doi: 10.1080/14740338.2019.1574295 PMID: 30676113
  11. Domagała-Rodacka, R.; Cibor, D.; Szczeklik, K.; Rodacki, T.; Mach, T.; Owczarek, D. Gastrointestinal tract as a side-effect target of medications. Przegl. Lek., 2016, 73(9), 652-658. PMID: 29688675
  12. Nyambe, M.; Koekemoer, T.; van de Venter, M.; Goosen, E.; Beukes, D. In vitro evaluation of the phytopharmacological potential of Sargassum incisifolium for the treatment of inflammatory bowel diseases. Medicines (Basel), 2019, 6(2), 49. doi: 10.3390/medicines6020049 PMID: 30959861
  13. Qu, L.; Liu, Q.; Zhang, Q.; Tuo, X.; Fan, D.; Deng, J.; Yang, H. Kiwifruit seed oil prevents obesity by regulating inflammation, thermogenesis, and gut microbiota in high-fat diet-induced obese C57BL/6 mice. Food Chem. Toxicol., 2019, 125, 85-94. doi: 10.1016/j.fct.2018.12.046 PMID: 30597221
  14. Cavalcante Silva, J; Grasseli, E; Canesi, L; Palombo, D; Abdalla, D. P310 A new dual-PPAR agonist (GQ-11), prevents ischemiareperfusion damage in rats after supraceliac aorta clamping. Eur Heart J-Cardiovas Imag, 2019, 20(Supplement_3), jez148.038.
  15. Stine, R.R.; Sakers, A.P.; TeSlaa, T.; Kissig, M.; Stine, Z.E.; Kwon, C.W.; Cheng, L.; Lim, H.W.; Kaestner, K.H.; Rabinowitz, J.D.; Seale, P. PRDM16 maintains homeostasis of the intestinal epithelium by controlling region-specific metabolism. Cell Stem Cell, 2019, 25(6), 830-845.e8. doi: 10.1016/j.stem.2019.08.017 PMID: 31564549
  16. Delvaux, M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut, 2002, 51(Suppl 1)(Suppl. 1), i67-i71. doi: 10.1136/gut.51.suppl_1.i67 PMID: 12077070
  17. Hockley, J.R.F.; Boundouki, G.; Cibert-Goton, V.; McGuire, C.; Yip, P.K.; Chan, C.; Tranter, M.; Wood, J.N.; Nassar, M.A.; Blackshaw, A.L.; Aziz, Q.; Michael, G.J.; Baker, M.D.; Winchester, W.J.; Knowles, C.H.; Bulmer, D.C. Multiple roles for NaV1.9 in the activation of visceral afferents by noxious inflammatory, mechanical, and human disease–derived stimuli. Pain, 2014, 155(10), 1962-1975. doi: 10.1016/j.pain.2014.06.015 PMID: 24972070
  18. Kanazawa, M.; Hongo, M.; Fukudo, S. Visceral hypersensitivity in irritable bowel syndrome. J. Gastroenterol. Hepatol., 2011, 26(s3)(Suppl. 3), 119-121. doi: 10.1111/j.1440-1746.2011.06640.x PMID: 21443723
  19. Sarnelli, G.; Vandenberghe, J.; Tack, J. Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract. Dig. Liver Dis., 2004, 36(6), 371-376. doi: 10.1016/S1590-8658(04)00082-9 PMID: 15248374
  20. Schumacher, M.A. Transient receptor potential channels in pain and inflammation: therapeutic opportunities. Pain Pract., 2010, 10(3), 185-200. doi: 10.1111/j.1533-2500.2010.00358.x PMID: 20230457
  21. Farmer, A.D.; Aziz, Q. Gut pain & visceral hypersensitivity. Br. J. Pain, 2013, 7(1), 39-47. doi: 10.1177/2049463713479229 PMID: 26516496
  22. Keohane, J.; Quigley, E.M.M. Functional dyspepsia: The role of visceral hypersensitivity in its pathogenesis. World J. Gastroenterol., 2006, 12(17), 2672-2676. doi: 10.3748/wjg.v12.i17.2672 PMID: 16718751
  23. Keszthelyi, D.; Troost, F.J.; Masclee, A.A. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 303(2), G141-G154. doi: 10.1152/ajpgi.00060.2012 PMID: 22595988
  24. Spiller, R.; Lam, C. The shifting interface between IBS and IBD. Curr. Opin. Pharmacol., 2011, 11(6), 586-592. doi: 10.1016/j.coph.2011.09.009 PMID: 22000604
  25. Villani, A.C.; Lemire, M.; Thabane, M.; Belisle, A.; Geneau, G.; Garg, A.X.; Clark, W.F.; Moayyedi, P.; Collins, S.M.; Franchimont, D.; Marshall, J.K. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology, 2010, 138(4), 1502-1513. doi: 10.1053/j.gastro.2009.12.049 PMID: 20044998
  26. Klooker, T.K.; Braak, B.; Koopman, K.E.; Welting, O.; Wouters, M.M.; van der Heide, S.; Schemann, M.; Bischoff, S.C.; van den Wijngaard, R.M.; Boeckxstaens, G.E. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut, 2010, 59(9), 1213-1221. doi: 10.1136/gut.2010.213108 PMID: 20650926
  27. Tsang, S.W.; Zhao, M.; Wu, J.; Sung, J.J.Y.; Bian, Z.X. Nerve growth factor‐mediated neuronal plasticity in spinal cord contributes to neonatal maternal separation‐induced visceral hypersensitivity in rats. Eur. J. Pain, 2012, 16(4), 463-472. doi: 10.1016/j.ejpain.2011.07.005 PMID: 22396076
  28. Russo, E.B. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res., 2016, 1(1), 154-165. doi: 10.1089/can.2016.0009 PMID: 28861491
  29. Mawe, G.M.; Coates, M.D.; Moses, P.L. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment. Pharmacol. Ther., 2006, 23(8), 1067-1076. doi: 10.1111/j.1365-2036.2006.02858.x PMID: 16611266
  30. Kim, J.J.; Kim, N.; Choi, Y.J.; Kim, J.S.; Jung, H.C. Increased TRPV1 and PAR2 mRNA expression levels are associated only with the esophageal reflux symptoms, but not with the extraesophageal reflux symptoms. Medicine (Baltimore), 2016, 95(32), e4387. doi: 10.1097/MD.0000000000004387 PMID: 27512850
  31. Yoshida, N.; Kuroda, M.; Suzuki, T.; Kamada, K.; Uchiyama, K.; Handa, O.; Takagi, T.; Yoshikawa, T.; Kuramoto, H. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig. Dis. Sci., 2013, 58(8), 2237-2243. doi: 10.1007/s10620-012-2337-7 PMID: 22899239
  32. Sarkar, S.; Hobson, A.R.; Furlong, P.L.; Woolf, C.J.; Thompson, D.G.; Aziz, Q. Central neural mechanisms mediating human visceral hypersensitivity. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 281(5), G1196-G1202. doi: 10.1152/ajpgi.2001.281.5.G1196 PMID: 11668028
  33. Tack, J.; Vanuytsel, T.; Pauwels, A. Established and emerging treatment options for functional heartburn and chest pain. Curr. Treat. Options Gastroenterol., 2016, 14(1), 19-27. doi: 10.1007/s11938-016-0081-3 PMID: 26825704
  34. Van Handel, D.; Fass, R. The pathophysiology of non-cardiac chest pain. J. Gastroenterol. Hepatol., 2005, 20(s3)(Suppl.), S6-S13. doi: 10.1111/j.1440-1746.2005.04165.x PMID: 16359347
  35. Lee, J.Y.; Kim, N.; Park, J.H.; Nam, R.H.; Lee, S.M.; Song, C.H.; Kim, G.; Na, H.Y.; Choi, Y.J.; Kim, J.J.; Lee, D.H. Expression of neurotrophic factors, tight junction proteins, and cytokines according to the irritable bowel syndrome subtype and sex. J. Neurogastroenterol. Motil., 2020, 26(1), 106-116. doi: 10.5056/jnm19099 PMID: 31623029
  36. Naveed, M.; Hejazi, V.; Abbas, M.; Kamboh, A.A.; Khan, G.J.; Shumzaid, M.; Ahmad, F.; Babazadeh, D. FangFang, X.; Modarresi-Ghazani, F.; WenHua, L.; XiaoHui, Z. Chlorogenic acid (CGA): A pharmacological review and call for further research. Biomed. Pharmacother., 2018, 97, 67-74. doi: 10.1016/j.biopha.2017.10.064 PMID: 29080460
  37. Sikandar, S.; Dickenson, A.H. Visceral pain. Curr. Opin. Support. Palliat. Care, 2012, 6(1), 17-26. doi: 10.1097/SPC.0b013e32834f6ec9 PMID: 22246042
  38. Fukudo, S.; Kuwano, H.; Miwa, H. Management and pathophysiology of functional gastrointestinal disorders. Digestion, 2012, 85(2), 85-89. doi: 10.1159/000334652 PMID: 22269284
  39. Ritchie, J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut, 1973, 14(2), 125-132. doi: 10.1136/gut.14.2.125 PMID: 4696535
  40. Taki, M.; Oshima, T.; Li, M.; Sei, H.; Tozawa, K.; Tomita, T.; Fukui, H.; Watari, J.; Miwa, H. Duodenal low‐grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol. Motil., 2019, 31(10), e13576. doi: 10.1111/nmo.13576 PMID: 30790378
  41. Cremon, C.; Carini, G.; Wang, B.; Vasina, V.; Cogliandro, R.F.; De Giorgio, R.; Stanghellini, V.; Grundy, D.; Tonini, M.; De Ponti, F.; Corinaldesi, R.; Barbara, G. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am. J. Gastroenterol., 2011, 106(7), 1290-1298. doi: 10.1038/ajg.2011.86 PMID: 21427712
  42. Barbara, G.; Cremon, C.; De Giorgio, R.; Dothel, G.; Zecchi, L.; Bellacosa, L.; Carini, G.; Stanghellini, V.; Corinaldesi, R. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr. Gastroenterol. Rep., 2011, 13(4), 308-315. doi: 10.1007/s11894-011-0195-7 PMID: 21537962
  43. Akbar, A.; Walters, J.R.F.; Ghosh, S. Review article: visceral hypersensitivity in irritable bowel syndrome: Molecular mechanisms and therapeutic agents. Aliment. Pharmacol. Ther., 2009, 30(5), 423-435. doi: 10.1111/j.1365-2036.2009.04056.x PMID: 19493256
  44. Lee, K.N.; Lee, O.Y. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J. Gastroenterol., 2014, 20(27), 8886-8897. PMID: 25083061
  45. Ceuleers, H.; Van Spaendonk, H.; Hanning, N.; Heirbaut, J.; Lambeir, A.M.; Joossens, J.; Augustyns, K.; De Man, J.G.; De Meester, I.; De Winter, B.Y. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. World J. Gastroenterol., 2016, 22(47), 10275-10286. doi: 10.3748/wjg.v22.i47.10275 PMID: 28058009
  46. Lackner, J.M.; Gudleski, G.D.; Thakur, E.R.; Stewart, T.J.; Iacobucci, G.J.; Spiegel, B.M.R. The impact of physical complaints, social environment, and psychological functioning on IBS patients’ health perceptions: looking beyond GI symptom severity. Am. J. Gastroenterol., 2014, 109(2), 224-233. doi: 10.1038/ajg.2013.410 PMID: 24419481
  47. Pradhan, K.; Thakur, D.; Sudhan, N. Therapeutic efficacy of Punica granatum and Cucurbita maxima against clinical cases of nematodiasis in calves. Indian J. Indigenous Med, 1993.
  48. Carroll, S.Y.; O’Mahony, S.M.; Grenham, S.; Cryan, J.F.; Hyland, N.P. Disodium cromoglycate reverses colonic visceral hypersensitivity and influences colonic ion transport in a stress-sensitive rat strain. PLoS One, 2013, 8(12), e84718. doi: 10.1371/journal.pone.0084718 PMID: 24367692
  49. Camilleri, M.; Boeckxstaens, G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut, 2017, 66(5), 966-974. doi: 10.1136/gutjnl-2016-313425 PMID: 28232472
  50. Camilleri, M.; Ford, A. Pharmacotherapy for irritable bowel syndrome. J. Clin. Med., 2017, 6(11), 101. doi: 10.3390/jcm6110101 PMID: 29077050
  51. Nelson, A.D.; Camilleri, M.; Chirapongsathorn, S.; Vijayvargiya, P.; Valentin, N.; Shin, A.; Erwin, P.J.; Wang, Z.; Murad, M.H. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut, 2017, 66(9), 1611-1622. doi: 10.1136/gutjnl-2016-311835 PMID: 27287486
  52. Stanisor, O.I.; van Diest, S.A.; Yu, Z.; Welting, O.; Bekkali, N.; Shi, J.; de Jonge, W.J.; Boeckxstaens, G.E.; van den Wijngaard, R.M. Stress-induced visceral hypersensitivity in maternally separated rats can be reversed by peripherally restricted histamine-1-receptor antagonists. PLoS One, 2013, 8(6), e66884. doi: 10.1371/journal.pone.0066884 PMID: 23776699
  53. Riediger, C.; Schuster, T.; Barlinn, K.; Maier, S.; Weitz, J.; Siepmann, T. Adverse effects of antidepressants for chronic pain: A systematic review and meta-analysis. Front. Neurol., 2017, 8(307), 307. doi: 10.3389/fneur.2017.00307 PMID: 28769859
  54. Balemans, D.; Boeckxstaens, G.E.; Talavera, K.; Wouters, M.M. Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity. Am. J. Physiol. Gastrointest. Liver Physiol., 2017, 312(6), G635-G648. doi: 10.1152/ajpgi.00401.2016 PMID: 28385695
  55. Chan, C.L.H.; Facer, P.; Davis, J.B.; Smith, G.D.; Egerton, J.; Bountra, C.; Williams, N.S.; Anand, P. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet, 2003, 361(9355), 385-391. doi: 10.1016/S0140-6736(03)12392-6 PMID: 12573376
  56. Chen, L.; Ilham, S.J.; Feng, B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth. Pain Med., 2017, 7(2), e42747. doi: 10.5812/aapm.42747 PMID: 28824858
  57. Annaházi, A.; Róka, R.; Rosztóczy, A.; Wittmann, T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J. Gastroenterol., 2014, 20(20), 6031-6043. doi: 10.3748/wjg.v20.i20.6031 PMID: 24876726
  58. Fuentes, I.M.; Christianson, J.A. Ion channels, ion channel receptors, and visceral hypersensitivity in irritable bowel syndrome. Neurogastroenterol. Motil., 2016, 28(11), 1613-1618. doi: 10.1111/nmo.12979 PMID: 27781369
  59. Winston, JH.; Xu, GY.; Sarna, SK. Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology, 2010, 138(1), 294-304. doi: 10.1053/j.gastro.2009.09.054
  60. Iwata, Y.; Ando, K.; Taniguchi, K.; Koba, N.; Sugiura, A.; Sudo, M. Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg. Med. Chem. Lett., 2015, 25(2), 236-240. doi: 10.1016/j.bmcl.2014.11.062 PMID: 25499880
  61. Kikuchi, A.; Ohashi, K.; Sugie, Y.; Sugimoto, H.; Omura, H. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J. Pharmacol. Sci., 2008, 106(2), 219-224. doi: 10.1254/jphs.FP0071599 PMID: 18270474
  62. Castro, J.; Harrington, AM.; Hughes, PA.; Martin, CM.; Ge, P.; Shea, CM. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′, 5′-monophosphate. Gastroenterology, 2013, 145(6), 1334-1346.
  63. Zong, Y.; Zhu, S.; Zhang, S.; Zheng, G.; Wiley, J.W.; Hong, S. Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor‐mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human. Neurogastroenterol. Motil., 2019, 31(2), e13477. doi: 10.1111/nmo.13477 PMID: 30284340
  64. Roudsari, N.M.; Lashgari, N.A.; Momtaz, S.; Farzaei, M.H.; Marques, A.M.; Abdolghaffari, A.H. Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review. Daru, 2019, 27(2), 755-780. doi: 10.1007/s40199-019-00284-1 PMID: 31273572
  65. Tan, N.; Gwee, K.A.; Tack, J.; Zhang, M.; Li, Y.; Chen, M.; Xiao, Y. Herbal medicine in the treatment of functional gastrointestinal disorders: A systematic review with meta‐analysis. J. Gastroenterol. Hepatol., 2020, 35(4), 544-556. doi: 10.1111/jgh.14905 PMID: 31674057
  66. Hawrelak, J.A.; Wohlmuth, H.; Pattinson, M.; Myers, S.P.; Goldenberg, J.Z.; Harnett, J.; Cooley, K.; Van De Venter, C.; Reid, R.; Whitten, D.L. Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Complement. Ther. Med., 2020, 48, 102233. doi: 10.1016/j.ctim.2019.102233 PMID: 31987249
  67. Vandenberghe, A.; Schol, J.; Van den Houte, K.; Masuy, I.; Carbone, F.; Tack, J. Current and emerging therapeutic options for the management of functional dyspepsia. Expert Opin. Pharmacother., 2020, 21(3), 365-376. doi: 10.1080/14656566.2019.1707805 PMID: 31899982
  68. Pountos, I.; Theodora Georgouli, ; Howard Bird, ; Giannoudis, P. Nonsteroidal anti-inflammatory drugs: prostaglandins, indications, and side effects. Int. J. Infereron Cytokine Mediator Res., 2011, 3, 19. doi: 10.2147/IJICMR.S10200
  69. Lazzaroni, M.; Bianchi Porro, G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment. Pharmacol. Ther., 2004, 20(Suppl. 2), 48-58. doi: 10.1111/j.1365-2036.2004.02037.x PMID: 15335413
  70. Sostres, C.; Gargallo, C.J.; Lanas, A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther., 2013, 15(Suppl 3)(Suppl. 3), S3. doi: 10.1186/ar4175 PMID: 24267289
  71. Dolatabadi, F.; Abdolghaffari, A.H.; Farzaei, M.H.; Baeeri, M.; Ziarani, F.S.; Eslami, M.; Abdollahi, M.; Rahimi, R. The protective effect of melissa officinalis l. in visceral hypersensitivity in rat using 2 models of acid-induced colitis and stress-induced irritable bowel syndrome: A possible role of nitric oxide pathway. J. Neurogastroenterol. Motil., 2018, 24(3), 490-501. doi: 10.5056/jnm17035 PMID: 29879761
  72. Ribeiro, M.A.; Bernardo-Gil, M.G.; Esquível, M.M. Melissa officinalis, L.: study of antioxidant activity in supercritical residues. J. Supercrit. Fluids, 2001, 21(1), 51-60. doi: 10.1016/S0896-8446(01)00078-X
  73. Miraj, S.; Azizi, N.; Kiani, S. A review of chemical components and pharmacological effects of Melissa officinalis L. Pharm. Lett., 2016, 8(6), 229-237.
  74. Noguchi-Shinohara, M.; Ono, K.; Hamaguchi, T.; Iwasa, K.; Nagai, T.; Kobayashi, S.; Nakamura, H.; Yamada, M. Pharmacokinetics, safety and tolerability of melissa officinalis extract which contained rosmarinic acid in healthy individuals: A randomized controlled trial. PLoS One, 2015, 10(5), e0126422. doi: 10.1371/journal.pone.0126422 PMID: 25978046
  75. Alijaniha, F.; Naseri, M.; Afsharypuor, S.; Fallahi, F.; Noorbala, A.; Mosaddegh, M.; Faghihzadeh, S.; Sadrai, S. Heart palpitation relief with Melissa officinalis leaf extract: Double blind, randomized, placebo controlled trial of efficacy and safety. J. Ethnopharmacol., 2015, 164, 378-384. doi: 10.1016/j.jep.2015.02.007 PMID: 25680840
  76. Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.H.; Khani, M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: A double blind, randomised, placebo controlled trial. J. Neurol. Neurosurg. Psychiatry, 2003, 74(7), 863-866. doi: 10.1136/jnnp.74.7.863 PMID: 12810768
  77. Shakeri, A.; Sahebkar, A.; Javadi, B. Melissa officinalis L. – A review of its traditional uses, phytochemistry and pharmacology. J. Ethnopharmacol., 2016, 188, 204-228. doi: 10.1016/j.jep.2016.05.010 PMID: 27167460
  78. Son, H.J.; Jung, K.; Park, Y.H.; Jeon, H.J.; Kang, M.; Ryu, K.H.; Pyo, S.S.; Eutamene, H.; Bueno, L.; Sun, W.S. Inhibitory effects of SKI3246, the rhizome extract of Atractylodes japonica, on visceral hypersensitivity in experimental irritable bowel syndrome rat models. Arch. Pharm. Res., 2015, 38(5), 642-649. doi: 10.1007/s12272-014-0454-x PMID: 25070763
  79. Park, J.J.; Chon, N.R.; Lee, Y.J.; Park, H. The effects of an extract of Atractylodes japonica rhizome, SKI3246 on gastrointestinal motility in guinea pigs. J. Neurogastroenterol. Motil., 2015, 21(3), 352-360. doi: 10.5056/jnm14112 PMID: 26130631
  80. Kim, Y.C.; Jun, M.; Jeong, W.S.; Chung, S.K. antioxidant properties of flavone C‐glycosides from atractylodes japonica leaves in human low‐density lipoprotein oxidation. J. Food Sci., 2005, 70(9), S575-S580. doi: 10.1111/j.1365-2621.2005.tb08331.x
  81. Kim, J.H.; Lee, J.H.; Jeong, S.M.; Lee, B.H.; Yoon, I.S.; Lee, J.H.; Choi, S.H.; Nah, S.Y. Effect of ginseng saponins on a rat visceral hypersensitivity model. Biol. Pharm. Bull., 2005, 28(11), 2120-2124. doi: 10.1248/bpb.28.2120 PMID: 16272701
  82. Kim, J.; Nah, S. Effects of ginsenoside total saponins on experimental irritable bowel syndrome in rats. J. Ginseng Res., 2005, 29(2), 94-99. doi: 10.5142/JGR.2005.29.2.094
  83. Rocha, H.A.C.; Rocha, T.V.; Nóbrega, F.J.F.; Morais, L.C.S.; Diniz, M.F.F.M. Randomized controlled trial of Panax ginseng in patients with irritable bowel syndrome. Rev. Bras. Farmacogn., 2018, 28(2), 218-222. doi: 10.1016/j.bjp.2018.02.007
  84. Khanna, R.; MacDonald, J.K.; Levesque, B.G. Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. J. Clin. Gastroenterol., 2014, 48(6), 505-512. doi: 10.1097/MCG.0b013e3182a88357 PMID: 24100754
  85. Galeotti, N.; Di Cesare Mannelli, L.; Mazzanti, G.; Bartolini, A.; Ghelardini, C. Menthol: A natural analgesic compound. Neurosci. Lett., 2002, 322(3), 145-148. doi: 10.1016/S0304-3940(01)02527-7 PMID: 11897159
  86. Liu, B.; Fan, L.; Balakrishna, S.; Sui, A.; Morris, J.B.; Jordt, S.E. TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain, 2013, 154(10), 2169-2177. doi: 10.1016/j.pain.2013.06.043 PMID: 23820004
  87. Harrington, A.M.; Hughes, P.A.; Martin, C.M.; Yang, J.; Castro, J.; Isaacs, N.J.; Blackshaw, A.L.; Brierley, S.M. A novel role for TRPM8 in visceral afferent function. Pain, 2011, 152(7), 1459-1468. doi: 10.1016/j.pain.2011.01.027 PMID: 21489690
  88. Rich, G.; Shah, A.; Koloski, N.; Funk, P.; Stracke, B.; Köhler, S.; Holtmann, G. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol. Motil., 2017, 29(11), e13132. doi: 10.1111/nmo.13132 PMID: 28695660
  89. Botschuijver, S.; Welting, O.; Levin, E.; Maria-Ferreira, D.; Koch, E.; Montijn, R.C.; Seppen, J.; Hakvoort, T.B.M.; Schuren, F.H.J.; de Jonge, W.J.; van den Wijngaard, R.M. Reversal of visceral hypersensitivity in rat by Menthacarin ®, a proprietary combination of essential oils from peppermint and caraway, coincides with mycobiome modulation. Neurogastroenterol. Motil., 2018, 30(6), e13299. doi: 10.1111/nmo.13299 PMID: 29383802
  90. Yang, J.M.; Xian, Y.F.; Ip, P.S.P.; Wu, J.C.Y.; Lao, L.; Fong, H.H.S.; Sung, J.J.Y.; Berman, B.; Yeung, J.H.K.; Che, C.T. Schisandra chinensis reverses visceral hypersensitivity in a neonatal–maternal separated rat model. Phytomedicine, 2012, 19(5), 402-408. doi: 10.1016/j.phymed.2011.11.013 PMID: 22230486
  91. Amiri, M.; Navabi, J.; Shokoohinia, Y.; Heydarpour, F.; Bahrami, G.; Behbood, L.; Derakhshandeh, P.; Momtaz, S.; Farzaei, M.H. Efficacy and safety of a standardized extract from Achillea wilhelmsii C. Koch in patients with ulcerative colitis: A randomized double blind placebo-controlled clinical trial. Complement. Ther. Med., 2019, 45, 262-268. doi: 10.1016/j.ctim.2019.05.001 PMID: 31331572
  92. Lashgari, N.A.; Momeni Roudsari, N.; Khayatan, D.; Shayan, M.; Momtaz, S.; Roufogalis, B.D. Ginger and its constituents: Role in treatment of inflammatory bowel disease. Biofactors, 2021, 48(1), 7-21. PMID: 34882874
  93. Zhang, C.; Huang, Y.; Li, P.; Chen, X.; Liu, F.; Hou, Q. Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction. BMC Complement Med Ther., 2020, 20(1), 272. doi: 10.1186/s12906-020-03059-3
  94. Simrén, M.; Törnblom, H.; Palsson, OS.; Van Oudenhove, L.; Whitehead, WE.; Tack, J. Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology, 2019, 157(2), 391-402. doi: 10.1053/j.gastro.2019.04.019
  95. Shi, H.; Zhu, X.; Cui, Y.; Qin, Y.; Yang, L.; Deng, X. Analgesic activity of cynaropicrinon on post inflammatory irritable bowel syndrome visceral hypersensitivity in a rat model. Exp. Ther. Med., 2017, 14(5), 4476-4482. doi: 10.3892/etm.2017.5037 PMID: 29067122
  96. Rahimi, R.; Abdollahi, M. Herbal medicines for the management of irritable bowel syndrome: A comprehensive review. World J. Gastroenterol., 2012, 18(7), 589-600. doi: 10.3748/wjg.v18.i7.589 PMID: 22363129
  97. Abdollahi, M.; Esmaily, H.; Baeeri, M.; Asadi-Shahmirzadi, A.; Mozaffari, S.; Rahimi, R.; Sanei, Y.; Salehi-Surmaghi, M-H. Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Pharmacogn. Mag., 2011, 7(27), 213-223. doi: 10.4103/0973-1296.84235 PMID: 21969792
  98. Brinkhaus, B.; Hentschel, C.; Keudell, C.V.; Schindler, G.; Lindner, M.; Stützer, H.; Kohnen, R.; Willich, S.N.; Lehmacher, W.; Hahn, E.G.G. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: A randomized, placebo-controlled, double-blind clinical trial. Scand. J. Gastroenterol., 2005, 40(8), 936-943. doi: 10.1080/00365520510023134 PMID: 16173134
  99. Cooke, C.; Carr, I.; Abrams, K.; Mayberry, J. Arrowroot as a treatment for diarrhoea in irritable bowel syndrome patients: a pilot study. Arq. Gastroenterol., 2000, 37(1), 20-24. doi: 10.1590/S0004-28032000000100005 PMID: 10962623
  100. Uezono, Y.; Miyano, K. Visceral hypersensitivity in functional dyspepsia (FD): Therapeutic approaches to FD based on suppression of visceral hypersensitivity. Functional Dyspepsia; Springer: Cham, 2018, pp. 167-177. doi: 10.1007/978-981-13-1074-4_15
  101. Liu, C.Y.; Müller, M.H.; Glatzle, J.; Weiser, D.; Kelber, O.; Enck, P.; Grundy, D.; Kreis, M.E. The herbal preparation STW 5 (IberogastR) desensitizes intestinal afferents in the rat small intestine1. Neurogastroenterol. Motil., 2004, 16(6), 759-764. doi: 10.1111/j.1365-2982.2004.00576.x PMID: 15601426
  102. Hong, S.W.; Chun, J.; Park, S.; Lee, H.J.; Im, J.P.; Kim, J.S. Aloe vera is effective and safe in short-term treatment of irritable bowel syndrome: a systematic review and meta-analysis. J. Neurogastroenterol. Motil., 2018, 24(4), 528-535. doi: 10.5056/jnm18077 PMID: 30153721
  103. Asadi-Shahmirzadi, A.; Mozaffari, S.; Sanei, Y.; Baeeri, M.; Hajiaghaee, R.; Monsef-Esfahani, H.R.; Abdollahi, M. Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: Combination of antioxidant and spasmolytic effects. Chin. J. Integr. Med., 2012, 1-9. doi: 10.1007/s11655-012-1027-9 PMID: 23263994
  104. Davis, K.; Philpott, S.; Kumar, D.; Mendall, M. Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int. J. Clin. Pract., 2006, 60(9), 1080-1086. doi: 10.1111/j.1742-1241.2006.00980.x PMID: 16749917
  105. Malik, Z.; Baik, D.; Schey, R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr. Gastroenterol. Rep., 2015, 17(2), 9. doi: 10.1007/s11894-015-0429-1 PMID: 25715910
  106. Bogale, K.; Raup-Konsavage, W.; Dalessio, S.; Vrana, K.; Coates, M.D. Cannabis and cannabis derivatives for abdominal pain management in inflammatory bowel disease. Med. Cannabis Cannabinoids, 2021, 4(2), 97-106. doi: 10.1159/000517425 PMID: 35224429
  107. Ng, Q.X.; Koh, S.S.H.; Chan, H.W.; Ho, C.Y.X. Clinical use of curcumin in depression: a meta-analysis. J. Am. Med. Dir. Assoc., 2017, 18(6), 503-508. doi: 10.1016/j.jamda.2016.12.071 PMID: 28236605
  108. Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41(1), 40-59. doi: 10.1016/j.biocel.2008.06.010 PMID: 18662800
  109. Ak, T.; Gülçin, İ. Antioxidant and radical scavenging properties of curcumin. Chem. Biol. Interact., 2008, 174(1), 27-37. doi: 10.1016/j.cbi.2008.05.003 PMID: 18547552
  110. Dong, S.; Zeng, Q.; Mitchell, E.S.; Xiu, J.; Duan, Y.; Li, C.; Tiwari, J.K.; Hu, Y.; Cao, X.; Zhao, Z. Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLoS One, 2012, 7(2), e31211. doi: 10.1371/journal.pone.0031211 PMID: 22359574
  111. Ammon, H.; Wahl, M. Pharmacology of Curcuma longa. Planta Med., 1991, 57(1), 1-7. doi: 10.1055/s-2006-960004 PMID: 2062949
  112. Yu, Y.; Wu, S.; Li, J.; Wang, R.; Xie, X.; Yu, X.; Pan, J.; Xu, Y.; Zheng, L. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab. Brain Dis., 2015, 30(1), 47-55. doi: 10.1007/s11011-014-9554-z PMID: 24807589
  113. Zhi, L.; Dong, L.; Kong, D.; Sun, B.; Sun, Q.; Grundy, D.; Zhang, G.; Rong, W. Curcumin acts via transient receptor potential vanilloid-1 receptors to inhibit gut nociception and reverses visceral hyperalgesia. Neurogastroenterol. Motil., 2013, 25(6), e429-e440. doi: 10.1111/nmo.12145 PMID: 23638900
  114. Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Ren, H.; Hu, H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr. J., 2017, 16(1), 68. doi: 10.1186/s12937-017-0293-y PMID: 29020971
  115. Chung, J.H. Metabolic benefits of inhibiting cAMP-PDEs with resveratrol. Adipocyte, 2012, 1(4), 256-258. doi: 10.4161/adip.21158 PMID: 23700542
  116. Sale, S.; Verschoyle, R.D.; Boocock, D.; Jones, D.J.L.; Wilsher, N.; Ruparelia, K.C.; Potter, G.A.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br. J. Cancer, 2004, 90(3), 736-744. doi: 10.1038/sj.bjc.6601568 PMID: 14760392
  117. Frozza, R.L.; Bernardi, A.; Paese, K.; Hoppe, J.B.; Silva, T.; Battastini, A.M.O.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol., 2010, 6(6), 694-703. doi: 10.1166/jbn.2010.1161 PMID: 21361135
  118. Xu, Y.; Cui, S.Y.; Ma, Q.; Shi, J.; Yu, Y.; Li, J.X.; Zheng, L.; Zhang, Y.; Si, J.M.; Yu, Y.C. Trans-resveratrol ameliorates stress-induced irritable bowel syndrome-like behaviors by regulation of brain-gut axis. Front. Pharmacol., 2018, 9, 631. doi: 10.3389/fphar.2018.00631 PMID: 29962949
  119. Lu, Y.; Xu, H.; Han, Y.; Zhang, Y. Analgesic effect of resveratrol on colitis-induced visceral pain via inhibition of TRAF6/NF-κB signaling pathway in the spinal cord. Brain Res., 2019, 1724, 146464. doi: 10.1016/j.brainres.2019.146464 PMID: 31536729
  120. Parasuraman, S.; Anand David, A.V.; Arulmoli, R. Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn. Rev., 2016, 10(20), 84-89. doi: 10.4103/0973-7847.194044 PMID: 28082789
  121. Espley, R.V.; Butts, C.A.; Laing, W.A.; Martell, S.; Smith, H.; McGhie, T.K.; Zhang, J.; Paturi, G.; Hedderley, D.; Bovy, A.; Schouten, H.J.; Putterill, J.; Allan, A.C.; Hellens, R.P. Dietary flavonoids from modified apple reduce inflammation markers and modulate gut microbiota in mice. J. Nutr., 2014, 144(2), 146-154. doi: 10.3945/jn.113.182659 PMID: 24353343
  122. Yano, J.M.; Yu, K.; Donaldson, G.P.; Shastri, G.G.; Ann, P.; Ma, L.; Nagler, C.R.; Ismagilov, R.F.; Mazmanian, S.K.; Hsiao, E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell, 2015, 161(2), 264-276. doi: 10.1016/j.cell.2015.02.047 PMID: 25860609
  123. Qin, H.Y.; Zang, K.H.; Zuo, X.; Wu, X.A.; Bian, Z.X. Quercetin attenuates visceral hypersensitivity and 5-Hydroxytryptamine availability in Postinflammatory irritable bowel syndrome rats: role of Enterochromaffin cells in the Colon. J. Med. Food, 2019, 22(7), 663-671. doi: 10.1089/jmf.2018.4264 PMID: 30920336
  124. Andres, S.; Pevny, S.; Ziegenhagen, R.; Bakhiya, N.; Schäfer, B.; Hirsch-Ernst, K.I.; Lampen, A. Safety aspects of the use of quercetin as a dietary supplement. Mol. Nutr. Food Res., 2018, 62(1), 1700447. doi: 10.1002/mnfr.201700447 PMID: 29127724
  125. Mohammadinejad, R.; Ahmadi, Z.; Tavakol, S.; Ashrafizadeh, M. Berberine as a potential autophagy modulator. J. Cell. Physiol., 2019, 234(9), 14914-14926. doi: 10.1002/jcp.28325 PMID: 30770555
  126. Yu, Z.C.; Cen, Y.X.; Wu, B.H.; Wei, C.; Xiong, F.; Li, D.F.; Liu, T.T.; Luo, M.H.; Guo, L.L.; Li, Y.X.; Wang, L.S.; Wang, J.Y.; Yao, J. Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats. World J. Gastroenterol., 2019, 25(29), 3956-3971. doi: 10.3748/wjg.v25.i29.3956 PMID: 31413530
  127. Zhang, X.; Li, Z.; Leung, W.; Liu, L.; Xu, H.; Bian, Z. The analgesic effect of paeoniflorin on neonatal maternal separation-induced visceral hyperalgesia in rats. J. Pain, 2008, 9(6), 497-505. doi: 10.1016/j.jpain.2007.12.009 PMID: 18387856
  128. Zhang, X.J.; Chen, H.L.; Li, Z.; Zhang, H.Q.; Xu, H.X.; Sung, J.J.Y.; Bian, Z.X. Analgesic effect of paeoniflorin in rats with neonatal maternal separation-induced visceral hyperalgesia is mediated through adenosine A1 receptor by inhibiting the extracellular signal-regulated protein kinase (ERK) pathway. Pharmacol. Biochem. Behav., 2009, 94(1), 88-97. doi: 10.1016/j.pbb.2009.07.013 PMID: 19664651
  129. Chang, X.; Zhao, L.; Wang, J.; Lu, X.; Zhang, S. Sini-san improves duodenal tight junction integrity in a rat model of functional dyspepsia. BMC Complement. Altern. Med., 2017, 17(1), 432. doi: 10.1186/s12906-017-1938-2 PMID: 28854971
  130. Cai, L.; Jiejie, L.; Hu, Y.; Chen, W.; Wei, L.; He, Q. A efficacy and safety of modified sini san for treating poststroke depression: A meta-analysis of randomized controlled trials. Explore (NY), 2020. PMID: 32527684
  131. Moussa, L.; Bézirard, V.; Salvador-Cartier, C.; Bacquié, V.; Houdeau, E.; Théodorou, V. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats. Clin. Nutr., 2013, 32(1), 51-58. doi: 10.1016/j.clnu.2012.05.021 PMID: 22727545
  132. Lee, T.H.; Choi, J.J.; Kim, D.H.; Choi, S.; Lee, K.R.; Son, M.; Jin, M. Gastroprokinetic effects of DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber. Phytomedicine, 2008, 15(10), 836-843. doi: 10.1016/j.phymed.2008.02.019 PMID: 18490147
  133. Kim, E.R.; Min, B.H.; Lee, T.H.; Son, M.; Rhee, P.L. Effect of DA-9701 on colorectal distension-induced visceral hypersensitivity in a rat model. Gut Liver, 2014, 8(4), 388-393. doi: 10.5009/gnl.2014.8.4.388 PMID: 25071903
  134. Lee, S.P.; Lee, K.N.; Lee, O.Y.; Lee, H.L.; Jun, D.W.; Yoon, B.C.; Choi, H.S.; Hwang, S.J.; Lee, S.E. Effects of DA-9701, a novel prokinetic agent, on phosphorylated extracellular signal-regulated kinase expression in the dorsal root ganglion and spinal cord induced by colorectal distension in rats. Gut Liver, 2014, 8(2), 140-147. doi: 10.5009/gnl.2014.8.2.140 PMID: 24672654
  135. Gershon, M.D.; Tack, J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology, 2007, 132(1), 397-414. doi: 10.1053/j.gastro.2006.11.002 PMID: 17241888
  136. Madisch, A.; Melderis, H.; Mayr, G.; Sassin, I.; Hotz, J. A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study Z. Gastroenterol., 2001, 39(7), 511-517. doi: 10.1055/s-2001-16142 PMID: 11505331
  137. Müller, M.H.; Liu, C.Y.; Glatzle, J.; Weiser, D.; Kelber, O.; Enck, P.; Grundy, D.; Kreis, M.E. STW 5 (Iberogast®) reduces afferent sensitivity in the rat small intestine. Phytomedicine, 2006, 13(Suppl. 5), 100-106. doi: 10.1016/j.phymed.2006.03.014 PMID: 16713220
  138. Malfertheiner, P. STW 5 (Iberogast) therapy in gastrointestinal functional disorders. Dig. Dis., 2017, 35(S1)(Suppl. 1), 25-29. doi: 10.1159/000485410 PMID: 29421817
  139. Fan, H.; Qiu, M-Y.; Mei, J-J.; Shen, G-X.; Liu, S-L.; Chen, R. Effects of four regulating-intestine prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis. World J. Gastroenterol., 2005, 11(31), 4800-4806. doi: 10.3748/wjg.v11.i31.4800 PMID: 16097047
  140. Bian, Z.; Wu, T.; Liu, L.; Miao, J.; Wong, H.; Song, L.; Sung, J.J.Y. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J. Altern. Complement. Med., 2006, 12(4), 401-407. doi: 10.1089/acm.2006.12.401 PMID: 16722791
  141. Hu, X.G.; Xu, D.; Zhao, Y.; Yang, X.B.; Meng, J.; Shen, H.; Guo, J. The alleviating pain effect of aqueous extract from tong-xie-yao-fang, on experimental visceral hypersensitivity and its mechanism. Biol. Pharm. Bull., 2009, 32(6), 1075-1079. doi: 10.1248/bpb.32.1075 PMID: 19483318
  142. Pan, F.; Zhang, T.; Zhang, Y.; Xu, J.; Chen, F. Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome. Chin. J. Integr. Med., 2009, 15(3), 216-219. doi: 10.1007/s11655-009-0216-7 PMID: 19568715
  143. Yin, Y.; Zhong, L.; Wang, J.W.; Zhao, X.Y.; Zhao, W.J.; Kuang, H.X. Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P. World J. Gastroenterol., 2015, 21(15), 4536-4546. doi: 10.3748/wjg.v21.i15.4536 PMID: 25914462
  144. Bian, Z-X.; Zhang, M.; Han, Q-B.; Xu, H-X.; Sung, J.J. Analgesic effects of JCM-16021 on neonatal maternal separation-induced visceral pain in rats. World J. Gastroenterol., 2010, 16(7), 837-845. PMID: 20143462
  145. Huang, X; Zeng, B; Zhou, F; Wang, R; Zeng, H. Studies on Quality Standard for Kangtai Capsule. 2000(06). Trad Chin Drug Res Clinic Pharmacol, 2000, 6
  146. Chen, Y.L.; Huang, X.Q.; Xu, S.J.; Liao, J.B.; Wang, R.J.; Lu, X.F.; Xie, Y.L.; Zhou, F.S.; Su, Z.R.; Lai, X.P. Relieving visceral hyperalgesia effect of Kangtai capsule and its potential mechanisms via modulating the 5-HT and NO level in vivo. Phytomedicine, 2013, 20(3-4), 249-257. doi: 10.1016/j.phymed.2012.09.027 PMID: 23141427
  147. Mertz, H.; Naliboff, B.; Munakata, J.; Niazi, N.; Mayer, E.A. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology, 1995, 109(1), 40-52. doi: 10.1016/0016-5085(95)90267-8 PMID: 7797041
  148. Rivkin, A. Tegaserod maleate in the treatment of irritable bowel syndrome: A clinical review. Clin. Ther., 2003, 25(7), 1952-1974. doi: 10.1016/S0149-2918(03)80198-4 PMID: 12946544
  149. Sikander, A.; Rana, S.V.; Prasad, K.K. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin. Chim. Acta, 2009, 403(1-2), 47-55. doi: 10.1016/j.cca.2009.01.028 PMID: 19361459
  150. Farmer, A.D.; Aziz, Q. Visceral pain hypersensitivity in functional gastrointestinal disorders. Br. Med. Bull., 2009, 91(1), 123-136. doi: 10.1093/bmb/ldp026 PMID: 19620136
  151. Bortolotti, M.; Porta, S. Effect of red pepper on symptoms of irritable bowel syndrome: preliminary study. Dig. Dis. Sci., 2011, 56(11), 3288-3295. doi: 10.1007/s10620-011-1740-9 PMID: 21573941
  152. Tatsuta, M.; Iishi, H. Effect of treatment with Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment. Pharmacol. Ther., 1993, 7(4), 459-462. doi: 10.1111/j.1365-2036.1993.tb00120.x PMID: 8218760
  153. Shiratori, M.; Shoji, T.; Kanazawa, M.; Hongo, M.; Fukudo, S. Effect of rikkunshito on gastric sensorimotor function under distention. Neurogastroenterol. Motil., 2011, 23(4), 323-e156. doi: 10.1111/j.1365-2982.2010.01648.x PMID: 21175995
  154. Liu, J.; Kou, F.; Tan, X.; Dai, Y.; Xie, C. Li, X Hewei Jiangni granule alleviates visceral hypersensitivity in a rat model of non-erosive reflux disease via transient receptor potential channel signaling. J Trad Chin Med Sci, 2020, 7(2), 162-170. doi: 10.1016/j.jtcms.2020.05.002
  155. Zhang, S.; Zhao, L.; Wang, H.; Wang, C.; Huang, S.; Shen, H.; Wei, W.; Tao, L.; Zhou, T. Efficacy of modified LiuJunZi decoction on functional dyspepsia of spleen-deficiency and qi-stagnation syndrome: A randomized controlled trial. BMC Complement. Altern. Med., 2013, 13(1), 54. doi: 10.1186/1472-6882-13-54 PMID: 23453018
  156. Wang, X.; Wang, B.; Zhou, T. The study on the effects of Jianpi Liqi Decoction on rats with functional dyspepsia and its mechanism; Chin J Integr Tradition West Med Digest, 2012, pp. 297-300.
  157. Bellono, N.W.; Bayrer, J.R.; Leitch, D.B.; Castro, J.; Zhang, C.; O’Donnell, T.A. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell, 2017, 170(1), 185-198. doi: 10.1016/j.cell.2017.05.034
  158. Zhao, J.; Zhao, L.; Zhang, S.; Zhu, C. Modified Liu-Jun-Zi decoction alleviates visceral hypersensitivity in functional dyspepsia by regulating EC cell-5HT3r signaling in duodenum. J. Ethnopharmacol., 2020, 250, 112468. doi: 10.1016/j.jep.2019.112468 PMID: 31836517
  159. Moazzam, S.W.; Mobeen, A.; Siddiqui, M.A. Efficacy of Jawarish Shahi a herbal formulation in irritable bowel syndrome: An open-labeled single-arm clinical trial. J. Tradit. Complement. Med., 2022, 12(6), 529-535. doi: 10.1016/j.jtcme.2022.04.004 PMID: 36325243
  160. Mobeen, A.; Moazzam, S.W. Jawarish Shahi: A special dosage form of herbal formulations for functional gastrointestinal disorders in Unani medicine- A comprehensive review. J. Ethnopharmacol., 2022, 293, 115319. doi: 10.1016/j.jep.2022.115319 PMID: 35490900

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers